Ensuring Access to FDA-Approved Alzheimer’s Treatment
Great progress has been made to advance Alzheimer’s and dementia research, providing hope to families in the midst of a terrible disease. And now that the Food and Drug Administration (FDA) has approved Alzheimer’s treatments to slow its progression at an early stage, it’s lifted that hope higher.
Thanks to relentless AIM advocacy and bipartisan support from congressional champions, the Centers for Medicare & Medicaid Services (CMS) announced they will enable coverage of FDA traditionally approved Alzheimer’s treatments through a low touch registry. We remain committed to working with policymakers to ensure existing and emerging treatments are accessible and affordable for everyone.
Be a Champion in the Fight to End Alzheimer’s
Our voices are stronger together. Help AIM advance legislation to improve the lives of people impacted by Alzheimer’s and all other dementia.
- Share your story with elected officials
- Engage on social media
- Write a letter to the editor
The following resources will help you learn more about how you can stay engaged and help ensure access to FDA-approved Alzheimer’s treatments.
- Alzheimer's Association Letter to HHS/CMS - May 2023
- Alzheimer’s Association Welcomes U.S. FDA Traditional Approval of Leqembi: Full Details
- Alzheimer’s Association Welcomes Announcement of CMS Coverage for FDA-approved Treatments
- Alzheimer's Treatments Senate Letter to CMS & HHS - February 2023
- Alzheimer's Treatments House Letter to CMS & HHS - January 2023
- Alzheimer's Treatments House Letter to HHS/CMS - June 2023
- Bipartisan Attorneys General Letter Urging Access to Alzheimer’s Treatments
- CMS Treatment Coverage Policy: What it Means for People Living with Alzheimer's
- Treatment Fact Sheet
- Written Testimony from Early-Stage Advisor Tony Gonzales: House Ways & Means Committee
Find a Member of Congress
Learn where your member of Congress stands on AIM’s policy priorities and how you can help gain their support in the fight to end Alzheimer’s and all other dementia.